58809-98-6

Basic information

• Product Name: Propanedioic acid, methyl[4-nitro-3-(trifluoromethyl)phenyl]-, diethyl ester
• CAS NO: 58809-98-6
• Molecular Formula: C15H16F3NO6
• Molecular Weight: 363.29
• Mol File: 58809-98-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Propanedioic acid, methyl[4-nitro-3-(trifluoromethyl)phenyl]-, diethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Propanedioic acid, methyl[4-nitro-3-(trifluoromethyl)phenyl]-, diethyl ester(58809-98-6)
• EPA Substance Registry System: Propanedioic acid, methyl[4-nitro-3-(trifluoromethyl)phenyl]-, diethyl ester(58809-98-6)

Safety Data

• Hazardous Substances Data: 58809-98-6(Hazardous Substances Data)

Upstream product

• 393-09-9 4-fluoro-1-nitro-2-trifluoromethyl-benzene 
• 609-08-5 Diethyl methylmalonate 
• 118-83-2 5-chloro-2-nitrotrifluoromethylbenzene 

Downstream Products

• 138568-98-6 2-Methyl-2-(4-thiazol-2-yl-3-trifluoromethyl-phenyl)-malonic acid diethyl ester 
• 138568-97-5 2-Methyl-2-(4-thiocarbamoyl-3-trifluoromethyl-phenyl)-malonic acid diethyl ester 
• 138568-96-4 2-(4-Cyano-3-trifluoromethyl-phenyl)-2-methyl-malonic acid diethyl ester 
• 132483-39-7 2-<4-(Thiazol-2-yl)-3-trifluoromethylphenyl>propionic Acid 
• 58810-02-9 diethyl α-methyl-α-(3-trifluoromethyl-4-aminophenyl)-malonate 

Relevant articles and documents

Inhibitor for AKR1C3 or pharmaceutically acceptable salt of inhibitor as well as preparation method and application of inhibitor or pharmaceutically acceptable salt

The invention discloses an inhibitor for AKR1C3 or a pharmaceutically acceptable salt of the inhibitor as well as a preparation method and application of the inhibitor or the pharmaceutically acceptable salt. Non-steroidal anti-inflammatory drug flurbiprofen is used as a lead compound for structural optimization. The invention discloses the biphenyl-based AKR1C3 inhibitor represented by a formula(I) shown in the specification and the preparation method of the inhibitor. Target activity tests prove that the compounds provided by the invention can significantly inhibit activity of AKR1C3, and can be further used for development of a drug for treating and/or preventing diseases by inhibiting the aldo-keto reductase AKR1C3; and a molecular basis is laid for drug resistance-related mechanisticstudy of tumors.

Tertiary aminoacids

New α-(cyclic tert. aminophenyl)-aliphatic acids, e.g. those of the formula STR1 and functional derivatives thereof, are anti-inflammatory agents.